Neurosense Therapeutics Ltd. NRSN 深 沪
等待开盘 10-06 09:30:00 美东时间
4.03
+0.095
+2.41%
华盛通- 最 高7.50
- 今 开4.06
- 成交量 1.22万股
- 最 低 0.33
- 昨 收 3.935
- 总市值 433.97万
- 52周最高 7.50
- 市盈率 静 --
- 换手率 1.13%
- 52周最低 0.25
- 委 比 99.20%
- 总股本 107.68万
- 历史最高 8.18
- 量 比 0.40
- 振 幅 182.21%
- 历史最低 0.25
- 每 手 1
- 风险率 1.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases,
10-03 04:16
NeuroSense Therapeutics Granted Australia Patent For Its PrimeC
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian
02-09 22:23
NeuroSense Therapeutics Granted U.S. Patent For Novel PrimeC Formulation
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeCPatent protection extends through 2042, adding four additional years to PrimeC's IP umbrella
2024-09-24 21:06
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis ...
2024-08-28 19:00
